Literature DB >> 12958227

Smallpox: residual antibody after vaccination.

Stephanie Gallwitz1, Ted Schutzbank, Richard L Heberling, S S Kalter, Jeffrey E Galpin.   

Abstract

Of all the microorganisms and toxins, poxviruses (Orthopoxvirus) have the greatest potential for use by terrorists. These viruses can spread rapidly through the environment following initial infection. In 1980, the World Health Organization Eradication Program discontinued vaccination for smallpox and declared that the disease had been eliminated. With the threat of smallpox virus as a bioterrorism weapon, questions have been asked about the persistence of protection (as offered by antibodies) following vaccination with vaccinia virus vaccine. To address this, sera from 204 adults vaccinated as children were tested by enzyme immunoassay (EIA) for the presence of vaccinia virus antibody. Of the 204 individuals whose sera were examined for the presence of vaccinia antibody, 165 (80.9%) had been vaccinated once and 39 (19.1%) had been vaccinated at least twice. Of the 165 sera from individuals vaccinated once, 112 (67.9%) were positive. Of the 39 sera from individuals vaccinated more than once, 31 (79.5%) were positive. The presence of a vaccination scar at the time of blood collection was not determined. Fifty-six nonvaccinated individuals, under 30 years of age, were tested by EIA; four of these (7.1%) were positive for vaccinia virus antibody by EIA. Forty-four EIA-positive and 16 EIA-negative sera were also tested by serum neutralization (SN) as a comparison with the EIA test results; one serum (negative by EIA) was SN positive. No attempt was made to ascertain any demographics other than age (date of birth) and "remembered" times of vaccination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958227      PMCID: PMC193776          DOI: 10.1128/JCM.41.9.4068-4070.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  6 in total

1.  Farewell to smallpox vaccination.

Authors:  I Arita
Journal:  Dev Biol Stand       Date:  1979

2.  [Biohazards due to Orthopoxvirus: should we re-vaccinate against smallpox?].

Authors:  A J Georges; M C Georges-Courbot
Journal:  Med Trop (Mars)       Date:  1999

Review 3.  Indications for smallpox vaccination: policies still differ.

Authors:  D Baxby
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

4.  The persistence of neutralizing antibodies after revaccination against smallpox.

Authors:  B el-Ad; Y Roth; A Winder; Z Tochner; T Lublin-Tennenbaum; E Katz; T Schwartz
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

Review 5.  Quest for life-long protection by vaccination.

Authors:  W R Dowdle; W A Orenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

6.  Human monkeypox.

Authors:  Z Jezek; A I Gromyko; M V Szczeniowski
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1983
  6 in total
  7 in total

1.  Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.

Authors:  Jesse D Troy; Heather R Hill; Marian G Ewell; Sharon E Frey
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection.

Authors:  Kevin L Karem; Mary Reynolds; Christine Hughes; Zach Braden; Pragati Nigam; Shane Crotty; John Glidewell; Rafi Ahmed; Rama Amara; Inger K Damon
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

3.  An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling.

Authors:  Lichen Jing; D Huw Davies; Tiana M Chong; Sookhee Chun; Christopher L McClurkan; Jay Huang; Brian T Story; Douglas M Molina; Siddiqua Hirst; Philip L Felgner; David M Koelle
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

4.  The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose.

Authors:  Kavita Singh; Apostolos G Gittis; Rossitza K Gitti; Stanley A Ostazeski; Hua-Poo Su; David N Garboczi
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

5.  Serological Immunity to Smallpox in New South Wales, Australia.

Authors:  Valentina Costantino; Mallory J Trent; John S Sullivan; Mohana P Kunasekaran; Richard Gray; Raina MacIntyre
Journal:  Viruses       Date:  2020-05-18       Impact factor: 5.048

6.  A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.

Authors:  Xiaoxing Huang; Bin Lu; Wenbo Yu; Qing Fang; Li Liu; Ke Zhuang; Tingting Shen; Haibo Wang; Po Tian; Linqi Zhang; Zhiwei Chen
Journal:  PLoS One       Date:  2009-01-13       Impact factor: 3.240

7.  Alternative Routes of Zoonotic Vaccinia Virus Transmission, Brazil.

Authors:  Galileu B Costa; Iara A Borges; Pedro A Alves; Júlia B Miranda; Ana Paula M F Luiz; Paulo C P Ferreira; Jônatas S Abrahão; Elizabeth C Moreno; Erna G Kroon; Giliane de Souza Trindade
Journal:  Emerg Infect Dis       Date:  2015-12       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.